EuroScore 2 for identification of patients for transapical aortic valve replacement - a single center retrospective in 206 patients

Journal of Cardiothoracic Surgery

Ajay Moza²  Jan Spillner¹  Lachmandath Tewarie¹  Hülya Yildirim¹  Dumitrita-Alina Gafencu¹  George L Gafencu¹  Heike Schnöring¹  Imke Deppe¹  Andreas Goetzenich¹ 

[1] Clinic for Cardiothoracic and Vascular Surgery, University Clinic RWTH Aachen, Pauwelsstr. 30, Aachen 52074, Germany;Transplantation and Cardiac Surgery, The Royal Brompton and Harefield Trust, Harefield, United Kingdom

关键词: Valve disease;    Transapical valve replacement;    Risk models;   

Others  :  1152849
DOI  :  10.1186/1749-8090-7-89

 received in 2012-03-19, accepted in 2012-09-18,  发布年份 2012

【 摘 要 】

Background

Operative risk scoring algorithms identify patients with severe AS for transcatheter valve implantation in whom the anticipated operative mortality for conventional surgery would be considered prohibitive. We compared the three risk scores EuroScore 1 (LES), society of thoracic surgeons’ (STS) score and ACEF (age-creatinine-ejection fraction score) to the readjusted EuroScore 2 recently presented.

Methods

We reviewed all consecutive patients receiving either isolated conventional aortic valve replacement (cAVR) or transapical aortic valve implantation (TA-TAVI) in a two-year period (n = 206). 30-days mortality was considered as primary endpoint.

Results

TA-TAVI was performed in 76 patients, isolated cAVR in 130 patients. Overall mortality was 4.4% (TA-TAVI: 7.9%; cAVR: 2.3%). EuroScore 2 showed a good estimation for the entire population as well as within the subgroups: 4,02 ± 5,36% (TA-TAVI: 6.16 ± 7.14%, cAVR: 2.77 ± 3.42%). Predicted mortalities as assessed by LES were largely overestimated (TA-TAVI: 27.4 ± 20.9% cAVR: 10.6 ± 10.6%, sensitivity: 0.89, specificity: 0.71). STS predicted mortality was 6.3 ± 4.4% for TA-TAVI patients as to 3.2 ± 3.1% for cAVR patients (sens.: 0.22, spec.: 0.96) and ACEF predicted a mortality of 1.16 ± 0.36% for cAVR and 1.58 ± 0.59% for TA-TAVI patients (sens.: 0.78, spec.: 0.89).

Conclusion

The newly refined EuroScore 2 showed a good correlation within the studied population. For the individual patient, new cut-offs will have to be defined to triage patients for TAVI procedure. A drawback for complex score systems such as EuroScore and STS is the lack of recalibration to smaller populations as encountered in even large single centers.

【 授权许可】

   
2012 Goetzenich et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM: Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997, 29:630-634.
• [2]Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS, American College of Cardiology/American Heart Association Task Force: 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008, 118:e523-e661.
• [3]Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, Flachskampf F, Hall R, Iung B, Kasprzak J, Nataf P, Tornos P, Torracca L, Wenink A, ESC Committee for Practice Guidelines: Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007, 28:230-268.
• [4]Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Levang OW, Tornos P, Vanoverschelde JL, Vermeer F, Boersma E, Ravaud P, Vahanian A: A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003, 24:1231-1243.
• [5]Varadarajan P, Kapoor N, Bansal RC, Pai RG: Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg 2006, 82:2111-2115.
• [6]Figulla L, Neumann A, Figulla HR, Kahlert P, Erbel R, Neumann T: Transcatheter aortic valve implantation: evidence on safety and efficacy compared with medical therapy. A systematic review of current literature. Clin Res Cardiol 2011, 100:265-276.
• [7]Brown ML, Schaff HV, Sarano ME, Li Z, Sundt TM, Dearani JA, Mullany CJ, Orszulak TA: Is the European System for Cardiac Operative Risk Evaluation model valid for estimating the operative risk of patients considered for percutaneous aortic valve replacement? J Thorac Cardiovasc Surg 2008, 136:566-571.
• [8]Leontyev S, Walther T, Borger MA, Lehmann S, Funkat AK, Rastan A, Kempfert J, Falk V, Mohr FW: Aortic valve replacement in octogenarians: utility of risk stratification with EuroSCORE. Ann Thorac Surg 2009, 87:1440-1445.
• [9]Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, Lockowandt U: EuroSCORE II. Eur J Cardiothorac Surg 2012, 41:734-744. discussion 744–5
• [10]Biancari F, Vasques F, Mikkola R, Martin M, Lahtinen J, Heikkinen J: Validation of EuroSCORE II in Patients Undergoing Coronary Artery Bypass Surgery. Ann Thorac Surg 2012, 93:1930-1935.
• [11]Piazza N, Wenaweser P, van Gameren M, Pilgrim T, Tzikas A, Tsikas A, Otten A, Nuis R, Onuma Y, Cheng JM, Kappetein AP, Boersma E, Juni P, de Jaegere P, Windecker S, Serruys PW: Relationship between the logistic EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality score in patients implanted with the CoreValve ReValving system–a Bern-Rotterdam Study. Am Heart J 2010, 159:323-329.
• [12]Wendt D, Osswald BR, Kayser K, Thielmann M, Tossios P, Massoudy P, Kamler M, Jakob H: Society of Thoracic Surgeons score is superior to the EuroSCORE determining mortality in high risk patients undergoing isolated aortic valve replacement. Ann Thorac Surg 2009, 88:468-474. discussion 474–5
• [13]Dewey TM, Brown D, Ryan WH, Herbert MA, Prince SL, Mack MJ: Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg 2008, 135:180-187.
• [14]Ranucci M, Castelvecchio S, Menicanti L, Frigiola A, Pelissero G: Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony. Circulation 2009, 119:3053-3061.
• [15]Mack MJ: Risk scores for predicting outcomes in valvular heart disease: how useful? Curr Cardiol Rep 2011, 13:107-112.
• [16]Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R: European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999, 16:9-13.
• [17]Ranucci M, Castelvecchio S, Menicanti LA, Scolletta S, Biagioli B, Giomarelli P: An adjusted EuroSCORE model for high-risk cardiac patients. Eur J Cardiothorac Surg 2009, 36:791-797.
• [18]Rescigno G, Aratari C, D’alfonso A, Matteucci S, Capestro F, Pierri MD, Torracca L: Minimal influence of traditional surgical risk factors on mortality in contemporary aortic valve replacement. J Cardiovasc Surg (Torino) 2012, 53:393-399.